What 'failed conservative care' actually means

Months of physiotherapy, a consistent exercise routine, weight loss efforts, and painkillers taken as directed — and the knee is still stopping you from walking to the shops, sleeping through the night, or getting up a flight of stairs without gripping the rail. For many patients, the frustration at this stage comes partly from not knowing whether this counts as a genuine clinical threshold, or whether they simply need to try harder or wait longer.

The answer is that 'failed conservative care' is a defined standard, not a judgment call. Clinicians generally look for at least three to six months of structured, consistent effort across all four pillars: supervised or guided physiotherapy, a sustained exercise programme, weight management where body weight is loading the joint, and appropriate analgesia taken regularly — not just on bad days. The key word is consistent. Dipping in and out of a programme, or completing a single course of physiotherapy a year ago, does not meet the threshold.

Equally important is what the failure signal looks like. It is functional, not radiological. A scan showing moderate osteoarthritic change does not alone confirm that conservative care has failed — many people with similar imaging live comfortably with well-managed symptoms. The signal that matters is a sustained pattern of limitation: persistent difficulty walking meaningful distances, sleep regularly disturbed by knee pain, or an inability to manage stairs without significant discomfort. A single post-activity flare, or a difficult week following increased exertion, does not meet the bar. The limitation needs to be consistent and present despite full engagement with the programme.

Understanding this distinction matters because it shapes what comes next — and because patients who genuinely have reached this threshold should feel confident that escalating to specialist assessment is clinically appropriate, not premature.

The middle tier: intra-articular injections before surgery

Between exhausted conservative care and the operating theatre sits a structured middle tier that many patients are unaware of — a range of intra-articular injections that address different aspects of knee OA and that clinicians typically consider before moving to a surgical conversation.

Corticosteroids deliver a potent anti-inflammatory effect directly into the joint. Relief tends to begin quickly and may last several months, which makes them most useful during acute inflammatory flares. They do not modify the underlying disease.

Hyaluronic acid (viscosupplementation) supplements the knee's natural synovial fluid, improving lubrication and shock absorption. Multiple meta-analyses and Cochrane reviews support symptomatic benefit — particularly in early-to-moderate disease — making this the most robustly evidenced injectable option beyond corticosteroids.

Platelet-rich plasma (PRP) concentrates growth factors from the patient's own blood and reintroduces them into the joint. Randomised trials support benefit in pain and function outcomes; which patient groups respond best and which preparation protocol is optimal remain active areas of research.

Polyacrylamide hydrogel (Arthrosamid®) is a single-injection option that integrates into the synovial membrane as a lasting mechanical cushion. Unlike hyaluronic acid, it is not metabolised or reabsorbed. A 2022 study (Maulana, Cole & Lee, Journal of Arthritis) documented a reduction in patellofemoral bone marrow lesions following a single injection in advanced knee OA patients, and published series suggest it may reduce pain and delay the need for joint replacement in selected patients. Prospective trial data are continuing to accumulate.

BMAC (bone marrow aspiration concentrate) and autologous protein solution (nStride APS) represent the most biologically intensive options, concentrating cells and anti-inflammatory proteins respectively. Published series report improvements in pain and function; large randomised controlled trial data are less available than for HA, so these sit at an earlier stage of the evidence ladder — a distinction that reflects study maturity rather than absence of benefit.

No single injection suits every patient. Disease stage, the compartment affected, and prior treatment response all shape which option a clinician would discuss first.

The surgical pathway when injections are not enough

Surgery for knee osteoarthritis is not a single option — it is a ladder, and which rung is appropriate depends heavily on age, the extent of joint involvement, and what the patient needs to return to.

Arthroscopy (keyhole washout or debridement) has a limited and declining role in OA. Evidence does not support it for generalised wear. It retains a place only in specific mechanical situations — a loose body causing the knee to lock, or a discrete meniscal tear contributing to symptoms — rather than as a general response to failed injections.

Osteotomy is a joint-preservation procedure that realigns the bones around the knee to shift load away from the damaged compartment. It suits younger, more active patients whose disease is confined to one compartment and whose joint is otherwise structurally sound. The aim is to buy years of function before replacement becomes necessary.

Partial knee arthroplasty replaces only the affected compartment — typically the inner or outer half, or the kneecap surface — while leaving healthy cartilage and bone intact. Where disease is genuinely compartmental, outcomes are well-documented and recovery is generally faster than after a full replacement.

Total knee arthroplasty (TKA) is the appropriate endpoint for end-stage, bone-on-bone arthritis in which all compartments are involved and quality of life is significantly affected. The NHS position is that it is appropriate only in a minority of patients for whom all other options have genuinely been tried. The long-term evidence base for TKA — in terms of pain relief and functional restoration — is among the strongest in elective orthopaedic surgery.

The decision between these options is not automatic. A specialist assessment weighs disease extent, functional demand, and patient preference before any surgical path is proposed.

Patient factors that shape which step comes next

Two patients can arrive at the same decision point — conservative care genuinely exhausted, knee still limiting daily life — and leave with completely different plans. The reason is that several patient-level factors interact, and a specialist weighs all of them together rather than applying a fixed protocol.

Age and activity level are among the strongest modifiers. Younger, more active patients generally benefit from joint-preservation strategies first — osteotomy or partial replacement — to maintain function before committing to a total replacement that may itself need revision decades later. Older patients with lower functional demand may reach the surgical conversation sooner.

Disease compartment opens or closes options: unicompartmental OA (only one section of the joint affected) is a different clinical problem from tricompartmental end-stage wear, where fewer alternatives to full replacement exist.

BMI matters at every tier. Excess weight reduces injection efficacy and increases surgical risk, which is why weight management remains part of the conversation well into the escalation pathway — not just at the conservative stage.

Symptom and imaging alignment also matters. Moderate changes on a scan with severe functional impairment may justify earlier escalation than the imaging grade alone would suggest.

Finally, patient goals shape what 'a good outcome' means. Someone hoping to return to recreational sport requires a different conversation than someone whose priority is walking without pain.

The practical effect of these interactions is significant. A 58-year-old with unicompartmental OA, a BMI of 31, and a goal of continuing to cycle may be a candidate for an injection trial followed by osteotomy — whereas a 72-year-old with tricompartmental bone-on-bone disease and the same level of pain is likely heading directly toward total knee arthroplasty. Same symptom burden; very different optimal paths.

When to ask for a specialist referral and what to expect

Seeking a specialist opinion is the right step when pain has become a consistent daily limit — not occasional, not post-activity, but persistently affecting sleep, mobility, or the basic demands of the day, after genuine non-surgical management has been tried and found wanting.

A first specialist appointment is an evaluation, not a surgical commitment. The clinician will take a full history, assess how the knee functions under load, and review existing imaging — typically X-rays, sometimes MRI. The purpose is to map where on the treatment pathway the patient sits, and whether any non-surgical options remain appropriate before a surgical conversation begins. The NHS position is consistent: surgery is right for only a minority of patients, and most who reach this stage are assessed for non-surgical routes first.

A GP referral is not a prerequisite for seeking an opinion. Existing scans and GP letters provide useful context, but an independent specialist assessment can be arranged without a formal referral in place.

What distinguishes a thorough assessment from a cursory one is not its length but its scope. A clinician who asks about functional goals — what the patient wants to return to, not just how much it hurts — and who works through the full tier of options before reaching for a surgical recommendation, is doing exactly what the evidence base supports. The structured pathway covered in this article exists precisely because most patients have more road left to travel than they realise.

1. [1] Knee replacement – NHS. https://www.nhs.uk/conditions/knee-replacement/ https://www.nhs.uk/conditions/knee-replacement/